Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 353
- Registration Number
- NCT01555099
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- King Saud University
- Target Recruit Count
- 945
- Registration Number
- NCT01524198
- Locations
- 🇸🇦
King Fahad Medical City, Riyadh, Saudi Arabia
Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Revalesio Corporation
- Target Recruit Count
- 65
- Registration Number
- NCT01511302
- Locations
- 🇺🇸
California Allergy and Asthma, Los Angeles, California, United States
🇺🇸Axis Clinical Trials, Los Angeles, California, United States
🇺🇸West Coast Clinical Trials, Costa Mesa, California, United States
Role of microRNAs in T Cell-Driven Inflammation in Asthma
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 55
- Registration Number
- NCT01484691
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Pharmacokinetic Pilot Study on Budesonide/Formoterol
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 17
- Registration Number
- NCT01457716
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Padagis LLC
- Target Recruit Count
- 55
- Registration Number
- NCT01453946
- Locations
- 🇵🇱
Research Site, Łódź, Poland
Safety Study of Entocort for Children With Crohn's Disease
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Padagis LLC
- Target Recruit Count
- 123
- Registration Number
- NCT01444092
- Locations
- 🇵🇱
Research Site, Łódź, Poland
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 214
- Registration Number
- NCT01360021
- Locations
- 🇷🇺
Research Site, Moscow, Russia, Russian Federation
Improvement of FeNO and FEF25-75 After Inhaled Corticosteroid Treatment of Asthma
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Chungbuk National University
- Target Recruit Count
- 93
- Registration Number
- NCT01340118
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju, Chungbuk, Korea, Republic of
Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9906
- Registration Number
- NCT01328964
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.